1. Home
  2. CPZ vs AGEN Comparison

CPZ vs AGEN Comparison

Compare CPZ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPZ
  • AGEN
  • Stock Information
  • Founded
  • CPZ 2019
  • AGEN 1994
  • Country
  • CPZ United States
  • AGEN United States
  • Employees
  • CPZ N/A
  • AGEN N/A
  • Industry
  • CPZ Trusts Except Educational Religious and Charitable
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CPZ Finance
  • AGEN Health Care
  • Exchange
  • CPZ Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • CPZ 304.3M
  • AGEN 286.0M
  • IPO Year
  • CPZ N/A
  • AGEN 2000
  • Fundamental
  • Price
  • CPZ $15.60
  • AGEN $7.30
  • Analyst Decision
  • CPZ
  • AGEN Buy
  • Analyst Count
  • CPZ 0
  • AGEN 2
  • Target Price
  • CPZ N/A
  • AGEN $54.50
  • AVG Volume (30 Days)
  • CPZ 63.0K
  • AGEN 938.2K
  • Earning Date
  • CPZ 01-01-0001
  • AGEN 08-06-2024
  • Dividend Yield
  • CPZ 11.07%
  • AGEN N/A
  • EPS Growth
  • CPZ N/A
  • AGEN N/A
  • EPS
  • CPZ N/A
  • AGEN N/A
  • Revenue
  • CPZ N/A
  • AGEN $161,416,000.00
  • Revenue This Year
  • CPZ N/A
  • AGEN $43.78
  • Revenue Next Year
  • CPZ N/A
  • AGEN N/A
  • P/E Ratio
  • CPZ N/A
  • AGEN N/A
  • Revenue Growth
  • CPZ N/A
  • AGEN 69.94
  • 52 Week Low
  • CPZ $13.17
  • AGEN $4.78
  • 52 Week High
  • CPZ $16.11
  • AGEN $34.20
  • Technical
  • Relative Strength Index (RSI)
  • CPZ 59.02
  • AGEN 28.20
  • Support Level
  • CPZ $15.22
  • AGEN $14.77
  • Resistance Level
  • CPZ $15.75
  • AGEN $18.74
  • Average True Range (ATR)
  • CPZ 0.22
  • AGEN 1.55
  • MACD
  • CPZ 0.04
  • AGEN -0.45
  • Stochastic Oscillator
  • CPZ 73.91
  • AGEN 8.62

About CPZ Calamos Long/Short Equity & Dynamic Income Trust

Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: